Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
J Hypertens Suppl. 2008 Sep; 26(3):S21-7.JH

Abstract

OBJECTIVES

The ADVANCE trial was designed to determine the effects of routine blood pressure lowering using a fixed combination of perindopril-indapamide on major vascular outcomes in patients with type 2 diabetes, regardless of initial blood pressure levels or the use of other blood pressure-lowering drugs, including angiotensin-converting enzyme inhibitors.

METHODS

After a 6-week run-in period, 11,140 high-risk individuals with type 2 diabetes were randomized to fixed combination perindopril-indapamide or matching placebo, in addition to current therapy. The two primary outcomes were composites of major macrovascular and major microvascular events, analysed jointly and separately by intention to treat.

RESULTS

The reduction in blood pressure in participants assigned to active treatment was 5.6/2.2 mmHg greater than that observed in the control group. Active treatment reduced the risk of the combined primary outcome, a major macrovascular or microvascular event by 9% (P = 0.041) and resulted in a 14% (P = 0.025) reduction in all-cause mortality and an 18% (P = 0.027) reduction in cardiovascular mortality. There were reductions of 14% (P = 0.02) in total coronary events and 21% (P < 0.0001) in total renal events. The treatment was well tolerated, with 73% and 74% of patients in the active treatment and placebo groups still adherent to randomized therapy after an average of 4.3 years of follow-up.

CONCLUSIONS

Routine treatment with the fixed combination of perindopril and indapamide was well tolerated and reduced the risk of death and major vascular events, regardless of the initial blood pressure level or concomitant treatments received. The results suggest that for every 79 patients treated in this manner, one death would be avoided over 5 years.

Authors+Show Affiliations

The George Institute for International Health, The University of Sydney and The Royal Prince Alfred Hospital, Camperdown, NSW, Australia. jchalmers@george.org.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19363849

Citation

Chalmers, John, et al. "Efficacy and Safety of Fixed Combination of Perindopril and Indapamide in Type 2 Diabetes: Results From ADVANCE in Context of Available Evidence." Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension, vol. 26, no. 3, 2008, pp. S21-7.
Chalmers J, Joshi R, Kengne AP, et al. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens Suppl. 2008;26(3):S21-7.
Chalmers, J., Joshi, R., Kengne, A. P., Ninomiya, T., Bi, Y., Bompoint, S., Billot, L., & Patel, A. (2008). Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension, 26(3), S21-7.
Chalmers J, et al. Efficacy and Safety of Fixed Combination of Perindopril and Indapamide in Type 2 Diabetes: Results From ADVANCE in Context of Available Evidence. J Hypertens Suppl. 2008;26(3):S21-7. PubMed PMID: 19363849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. AU - Chalmers,John, AU - Joshi,Rohina, AU - Kengne,Andre Pascal, AU - Ninomiya,Toshiharu, AU - Bi,Yufang, AU - Bompoint,Severine, AU - Billot,Laurent, AU - Patel,Anushka, AU - ,, PY - 2009/4/15/entrez PY - 2009/4/15/pubmed PY - 2009/5/12/medline SP - S21 EP - 7 JF - Journal of hypertension. Supplement : official journal of the International Society of Hypertension JO - J Hypertens Suppl VL - 26 IS - 3 N2 - OBJECTIVES: The ADVANCE trial was designed to determine the effects of routine blood pressure lowering using a fixed combination of perindopril-indapamide on major vascular outcomes in patients with type 2 diabetes, regardless of initial blood pressure levels or the use of other blood pressure-lowering drugs, including angiotensin-converting enzyme inhibitors. METHODS: After a 6-week run-in period, 11,140 high-risk individuals with type 2 diabetes were randomized to fixed combination perindopril-indapamide or matching placebo, in addition to current therapy. The two primary outcomes were composites of major macrovascular and major microvascular events, analysed jointly and separately by intention to treat. RESULTS: The reduction in blood pressure in participants assigned to active treatment was 5.6/2.2 mmHg greater than that observed in the control group. Active treatment reduced the risk of the combined primary outcome, a major macrovascular or microvascular event by 9% (P = 0.041) and resulted in a 14% (P = 0.025) reduction in all-cause mortality and an 18% (P = 0.027) reduction in cardiovascular mortality. There were reductions of 14% (P = 0.02) in total coronary events and 21% (P < 0.0001) in total renal events. The treatment was well tolerated, with 73% and 74% of patients in the active treatment and placebo groups still adherent to randomized therapy after an average of 4.3 years of follow-up. CONCLUSIONS: Routine treatment with the fixed combination of perindopril and indapamide was well tolerated and reduced the risk of death and major vascular events, regardless of the initial blood pressure level or concomitant treatments received. The results suggest that for every 79 patients treated in this manner, one death would be avoided over 5 years. SN - 0952-1178 UR - https://www.unboundmedicine.com/medline/citation/19363849/Efficacy_and_safety_of_fixed_combination_of_perindopril_and_indapamide_in_type_2_diabetes:_results_from_ADVANCE_in_context_of_available_evidence_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=19363849.ui DB - PRIME DP - Unbound Medicine ER -